(E)-3-(2,4-dimethoxyphenyl)-N-[2-[4-(2-methoxyethoxy)-3-(methylcarbamoylsulfamoyl)phenyl]ethyl]prop-2-enamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-(2,4-dimethoxyphenyl)-N-[2-[4-(2-methoxyethoxy)-3-(methylcarbamoylsulfamoyl)phenyl]ethyl]prop-2-enamide
• 化学式: C₂₄H₃₁N₃O₈S
• 分子量: 521.6
• InChiKey: YNNNKRCCCKGEQY-JXMROGBWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  36
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  150
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• CINNAMOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1183236A1

  公开（公告）日：2002-03-06
• Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
  申请人：Herlands Louis

  公开号：US20070026079A1

  公开（公告）日：2007-02-01

  Provided are methods of increasing K ATP channel activity in the hypothalamus of a mammal, methods of reducing glucose production in a mammal, methods of reducing peripheral glucose levels in a mammal, methods of reducing triglyceride levels in a mammal, methods of reducing very low density lipoprotein (VLDL) levels in a mammal, methods of methods of reducing gluconeogenesis in the liver of a mammal, methods of treating metabolic disorders such as diabetes, hyperglycemia, insulin resistance, glucose intolerance, metabolic syndrome and/or obesity, and methods of increasing glucose production and peripheral glucose levels in a mammal. Also provided are methods of treating heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, atherosclerosis, hypercholesterolemia, hypertension, polycystic ovary syndrome, gonadotropin deficiency and/or amenorrhea.
• Modulation of Hypothalamic Atp-Sensitive Potassium Channels
  申请人：Rossetti Luciano

  公开号：US20090012067A1

  公开（公告）日：2009-01-08

  Provided are methods of increasing K ATP activity in the hypothalamus of a mammal, methods of reducing glucose production and peripheral blood glucose levels in a mammal, methods of inhibiting gluconeogenesis in the liver of a mammal, and methods of increasing glucose production and peripheral blood glucose levels in a mammal.
• US6350778B1
  申请人：——

  公开号：US6350778B1

  公开（公告）日：2002-02-26
• [EN] CINNAMOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES<br/>[FR] DERIVES DE BENZENESULFONAMIDE SUBSTITUES PAR UN CINNAMOYLAMINOALKYLE
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2000071513A1

  公开（公告）日：2000-11-30

  The present invention relates to cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives of formula (I) in which A(1), A(2), A(3), R(1), R(2), R(3), R(4), X, Y and Z have the meanings indicated in the claims. The compounds of formula (I) are valuable pharmaceutical active compounds which exhibit, for example, an inhibitory action on ATP-sensitive potassium channels in the cardiac muscle and/or in the cardiac nerve and are suitable, for example, for the treatment of disorders of the cardiovascular system such as coronary heart disease, arrhythmias, cardiac insufficiency or cardiomyopathies, or for the prevention of sudden cardiac death or for improving decreased contractility of the heart. The invention further more relates to processes for the preparation of the compounds of formula (I), their use and pharmaceutical preparations comprising them.